<div class="container">

<table style="width: 100%;"><tr>
<td>scABEL.ad</td>
<td style="text-align: right;">R Documentation</td>
</tr></table>
<h2>
Iteratively adjusted alpha for ABEL
</h2>

<h3>Description</h3>

<p>This function iteratively adjusts alpha for the <abbr><span class="acronym">BE</span></abbr> decision
via Average Bioequivalence with Expanding Limits (<abbr><span class="acronym">ABEL</span></abbr>) based
on simulations in order to maintain the consumer risk at the nominal level.
</p>


<h3>Usage</h3>

<pre><code class="language-R">scABEL.ad(alpha = 0.05, theta0, theta1, theta2, CV,
          design = c("2x3x3", "2x2x4", "2x2x3"), regulator,
          n, alpha.pre = 0.05, imax = 100, tol, print = TRUE,
          details = FALSE, setseed = TRUE, nsims = 1e+06,
          sdsims = FALSE, progress)
</code></pre>


<h3>Arguments</h3>

<table>
<tr style="vertical-align: top;">
<td><code>alpha</code></td>
<td>

<p>Type I Error (<abbr><span class="acronym">TIE</span></abbr>) probability (nominal level of the test). Per
convention commonly set to 0.05.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta0</code></td>
<td>

<p>‘True’ or assumed T/R ratio. Defaults to 0.90 according to the two Lászlós if not given explicitly.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta1</code></td>
<td>

<p>Conventional lower <abbr><span class="acronym">ABE</span></abbr> limit to be applied in the mixed procedure
if <code>CVwR == CVswitch</code>. Also lower limit for the point estimate
constraint. Defaults to 0.80 if not given explicitly.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>theta2</code></td>
<td>

<p>Conventional upper <abbr><span class="acronym">ABE</span></abbr> limit to be applied in the mixed procedure
if <code>CVwR == CVswitch</code>. Also upper limit for the point estimate
constraint. Defaults to 1.25 if not given explicitly.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>CV</code></td>
<td>

<p>Intra-subject coefficient(s) of variation as ratio (not percent).
</p>

<ul>
<li>
<p> If given as a scalar (<code>length(CV) == 1</code>) the <em>same</em> CV of Test
and Reference is assumed (homoscedasticity, <code>CVwT==CVwR</code>).
</p>
</li>
<li>
<p> If given as a vector (<code>length(CV) == 2</code>), <em>i.e.</em>, assuming
heteroscedasticity, the CV of the Test <strong>must</strong> be given in <code>CV[1]</code> and the one of the Reference in the <code>CV[2]</code>.
</p>
</li>
</ul>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>design</code></td>
<td>

<p>Design of the study.<br><code>"2x3x3"</code> is the partial replicate design.<br><code>"2x2x4"</code> is a full replicate design with 2 sequences and 4 periods.<br><code>"2x2x3"</code> is a full replicate design with 2 sequences and 3 periods.<br>
Defaults to <code>"2x3x3"</code>. Details are given the section about Designs.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>regulator</code></td>
<td>

<p>Regulatory settings for the expanding of the <abbr><span class="acronym">BE</span></abbr> acceptance limits.
Choose from <code>"EMA"</code> (default), <code>"HC"</code>, <code>"GCC"</code>, or <code>"FDA"</code>. This argument
may also be given in lower case.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>n</code></td>
<td>

<p>Total sample size of the study or a vector of sample size / sequences.
If <code>n</code> leads to an unbalanced design (<em>i.e.</em>, is not a multiple of two
in the full replicate designs or not a multiple of three in the partial
replicate), the code tries to keep subjects / sequence as balanced as possible.<br>
In evaluating a particular <em>unbalanced</em> study <strong>always</strong> give <code>n</code>
as a vector.<br>
Only if <code>design = "2x2x3"</code> (TRT|RTR) the <em>order</em> of sample sizes
is important. <code>n[1]</code> is for sequence TRT and <code>n[2]</code> for sequence RTR.<br>
If <code>n</code> is missing, a sample size is estimated with target power 0.80 and pre-specified
alpha if defined. Otherwise, alpha is used.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>alpha.pre</code></td>
<td>

<p>Pre-specified alpha (optional). Must be <code>&lt;=alpha</code>. <abbr><span class="acronym">ABEL</span></abbr> will be
performed at level <code style="white-space: pre;">⁠alpha.pre⁠</code> and the <abbr><span class="acronym">TIE</span></abbr> assessed at level <code style="white-space: pre;">⁠alpha⁠</code>.<br>
Less powerful than adjusting alpha but an alternative in the critical region
of maximum inflation of the <abbr><span class="acronym">TIE</span></abbr>. In certain scenarios Bonferroni’s
0.025 is not sufficient to preserve the Type I Error (<em>e.g.</em>, the third example).<br>
Not recommended if <code>CVwR &gt;= 0.45</code> due to poor power characteristics.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>imax</code></td>
<td>

<p>Maximum number of steps in sample size search. Defaults to 100.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>tol</code></td>
<td>

<p>Desired accuracy (convergence tolerance). Defaults to 1E-6.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>print</code></td>
<td>

<p>If <code style="white-space: pre;">⁠TRUE⁠</code> (default), the function sends its results to the console.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>details</code></td>
<td>

<p>If <code>TRUE</code>, the <em>relative</em> change of the consumer risk in percent is shown.
Additionally information about the impact on power (for specified <code>theta0</code>
and target power 0.80), runtime, and number of simulations (iterations)
are given. Defaults to <code>FALSE</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>setseed</code></td>
<td>

<p>Simulations are dependent on the starting point of the (pseudo)
random number generator. To avoid differences in power for different
runs <code>set.seed(123456)</code> is issued if <code>setseed=TRUE</code> (default).
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>nsims</code></td>
<td>

<p>Number of simulations to be performed to estimate the (empirical)
<abbr><span class="acronym">TIE</span></abbr> error and in each iteration of adjusting alpha. The default value
1,000,000 = 1E+6 should not be lowered.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>sdsims</code></td>
<td>

<p>If <code>FALSE</code> (default) power is estimated by the respective ‘key’ statistics.
Recommended for speed reasons.<br>
Set to <code>TRUE</code> if results of <code>power.scABEL</code> are expected to
be inaccurate (partial replicate design with unbalanced sequences and/or heteroscedasticity
where CVwT &gt; CVwR) and subject data via <code>power.scABEL.sdsims</code> should
be simulated instead. Very time consuming (easily 100times slower)! Subject data
simulations are only supported for <code>regulator = "EMA"</code> and <code>regulator = "GCC"</code>.
</p>
</td>
</tr>
<tr style="vertical-align: top;">
<td><code>progress</code></td>
<td>

<p>Set to <code>TRUE</code> if a progress bar should be displayed. Ignored if <code>sdsims = FALSE</code>.
</p>
</td>
</tr>
</table>
<h3>Details</h3>

<p>The simulations are done via the distributional properties of the statistical
quantities necessary for assessing <abbr><span class="acronym">BE</span></abbr> based on <abbr><span class="acronym">ABEL</span></abbr>.
Simulations for the <abbr><span class="acronym">TIE</span></abbr> are performed at the upper (expanded) limit <em>U</em>
of the acceptance range. Due to the symmetry around 1 results are valid for the lower
(expanded) limit <em>L</em> as well.<br><em>U</em> at the <abbr><span class="acronym">EMA</span></abbr>’s and Health Canada’s <code>CVcap</code>, the <abbr><span class="acronym">GCC</span></abbr>’s for <em>any</em> CVwR &gt; 0.3:</p>
<pre>scABEL(CV = 0.5, reg = "EMA")[["upper"]]
[1] 1.43191
scABEL(CV = 0.57382, reg = "HC")[["upper"]]
[1] 1.5
scABEL(CV = 0.5, reg = "GCC")[["upper"]]
[1] 1.333333</pre>
<p>Simulated studies are evaluated by ANOVA (Method A) as recommended in the
<abbr><span class="acronym">EMA</span></abbr>’ Q&amp;A-document and by intra-subject contrasts if <code>regulator = "HC"</code>.
Health Canada requires a mixed-effects model which cannot be implemented in R.
However, intra-subjects contrasts are a sufficiently close approximation.<br>
The Type I Error in <abbr><span class="acronym">ABEL</span></abbr> depends only on <code>CVwR</code> and – to a
minor degree – the sample size. Algorithm:
</p>

<ol>
<li>
<p> The <abbr><span class="acronym">TIE</span></abbr> is assessed based on <code>alpha</code> (or <code>alpha.pre</code>)
and compared to the nominal level of the test <code>alpha</code>.
</p>
</li>
<li>
<p> If no inflation of the <abbr><span class="acronym">TIE</span></abbr> is found, the algorithm stops.
</p>
</li>
<li>
<p> Otherwise, alpha is iteratively adjusted (<em>i.e.</em>, <code>alpha.adj &lt;alpha</code>)
until no more relevant inflation of the <abbr><span class="acronym">TIE</span></abbr> is detected (<em>i.e.</em>,
<code>abs(TIE - alpha) &lt;= tol</code>).
</p>
</li>
</ol>
<h3>Value</h3>

<p>Sends results to the console if argument <code>print=TRUE</code> (default).<br>
Returns a list with the input, adjusted alpha, and Type I Error (for nominal
and adjusted alpha) if argument <code>print=FALSE</code>.<br>
If no adjustment is necessary, <code>NAs</code> will be returned for the respective
variables (<code>alpha.adj</code>, <code>TIE.adj</code>, <code>rel.change</code>, <code>pwr.adj</code>, <code>rel.loss</code>).
</p>


<h3>Designs</h3>

<p>Although some designs are more ‘popular’ than others, power calculations are valid for <em>all</em> of the following designs:
</p>

<table>
<tr>
<td style="text-align: left;">
    <code>"2x2x4"</code> </td>
<td style="text-align: left;"> TRTR | RTRT</td>
</tr>
<tr>
<td style="text-align: left;">
    </td>
<td style="text-align: left;"> TRRT | RTTR</td>
</tr>
<tr>
<td style="text-align: left;">
    </td>
<td style="text-align: left;"> TTRR | RRTT</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>"2x2x3"</code> </td>
<td style="text-align: left;"> TRT | RTR</td>
</tr>
<tr>
<td style="text-align: left;">
    </td>
<td style="text-align: left;"> TRR | RTT</td>
</tr>
<tr>
<td style="text-align: left;">
    <code>"2x3x3"</code> </td>
<td style="text-align: left;"> TRR | RTR | RRT
  </td>
</tr>
</table>
<h3>Warning </h3>

<p>See the Warning section of the function <code>power.scABEL</code> concerning
the power value agreement to the one obtained by simulations via subject data.
</p>


<h3>Note</h3>

<p>Specifying <code>theta0</code> is not necessary.<br>
If <code>theta0</code> <em>is not</em> given, achievable power for the common target
of 0.80 (both for <code>alpha</code> and adjusted alpha) will be estimated. If
<code>theta0</code> <em>is</em> specified, its value will be used; again for target power 0.80.<br>
If you are interested in other levels of power, use <code>sampleN.scABEL.ad</code>.
</p>
<p>The EMA’s method is currently recommended in other jurisdictions as well (<em>e.g.</em>, by the WHO;
in ASEAN States, Australia, Brazil, Egypt, the Eurasian Economic Union, New Zealand, and the East African Community).<br>
If CVwR &gt; 30%, <em>fixed</em> wider limits of 0.7500–1.3333 are recommended by the Gulf Cooperation Council (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates).
</p>


<h3>Author(s)</h3>

<p>H. Schütz
</p>


<h3>References</h3>

<p>Wonnemann M, Frömke C, Koch A. <em>Inflation of the Type I Error: Investigations on Regulatory Recommendations for Bioequivalence of Highly Variable Drugs.</em> Pharm Res. 2015;32(1):135–43. <a href="https://doi.org/10.1007/s11095-014-1450-z">doi:10.1007/s11095-014-1450-z</a>
</p>
<p>Muñoz J, Alcaide D, Ocaña J. <em>Consumer’s risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs.</em> Stat Med. 2015;35(12):1933–43. <a href="https://doi.org/10.1002/sim.6834">doi:10.1002/sim.6834</a>
</p>
<p>Labes D, Schütz H. <em>Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control.</em> Pharm Res. 2016;33(11):2805–14. <a href="https://doi.org/10.1007/s11095-016-2006-1">doi:10.1007/s11095-016-2006-1</a>
</p>
<p>Tóthfalusi L, Endrényi L. <em>Algorithms for Evaluating Reference Scaled Average Bioequivalence: Power, Bias, and Consumer Risk.</em> Stat Med. 2017;36(27):4378–90. <a href="https://doi.org/10.1002/sim.7440">doi:10.1002/sim.7440</a>
</p>
<p>Molins E, Cobo E, Ocaña J. <em>Two-Stage Designs Versus European Scaled Average Designs in Bioequivalence Studies for Highly Variable Drugs: Which to Choose?</em> Stat Med. 2017;36(30):4777–88. <a href="https://doi.org/10.1002/sim.7452">doi:10.1002/sim.7452</a>
</p>
<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Guideline on the Investigation of Bioequivalence.</em> London, 20 January 2010. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf">CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **</a>
</p>
<p>European Medicines Agency, Committee for Medicinal Products for Human Use. <em>Questions &amp; Answers: positions on specific questions addressed to the Pharmacokinetics Working Party (PKWP).</em> London, 19 November 2015. <a href="https://www.ema.europa.eu/en/documents/scientific-guideline/questions-and-answers-positions-specific-questions-addressed-pharmacokinetics-working-party_en.pdf">EMA/618604/2008 Rev. 13</a>
</p>
<p>Health Canada, Therapeutic Products Directorate. <em>Comparative Bioavailability Standards: Formulations Used for Systemic Effects, 2.1.1.8 Highly variable drug products</em> Ottawa, 08 June 2018. <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/applications-submissions/guidance-documents/bioavailability-bioequivalence/comparative-bioavailability-standards-formulations-used-systemic-effects.html#a2.1.1.8">online</a>
</p>
<p>Executive Board of the Health Ministers’ Council for GCC States. <em>The GCC Guidelines for Bioequivalence.</em> May 2021. <a href="https://web.archive.org/web/20220728114758/https://www.sfda.gov.sa/sites/default/files/2021-10/GCC_Guidelines_Bioequivalence.pdf">Version 3.0</a>
Saudi Food &amp; Drug Authority <em>The GCC Guidelines for Bioequivalence.</em> <a href="https://www.sfda.gov.sa/sites/default/files/2022-08/GCC_Guidelines_Bioequivalence31_0.pdf">Version 3.1</a>
</p>


<h3>See Also</h3>

<p><code>sampleN.scABEL.ad</code>, <code>power.scABEL</code>, <code>power.scABEL.sdsims</code>, <code>scABEL</code>
</p>


<h3>Examples</h3>

<pre><code class="language-R"># Using all defaults:
# TRR|RTR|RRT, target power 80% for assumed ratio 0.90 (estimated sample size 54),
# EMA regulatory settings (ABE limits and PE constraint 0.80 - 1.25),
# 1E+6 simulated studies.
# Not run: due to timing policy of CRAN for examples

scABEL.ad(CV = 0.3)
# Should result in adjusted alpha 0.03389 (TIE 0.5000, TIE for nominal alpha 0.07189).
#
# As above but subject data simulations.

scABEL.ad(CV = 0.3, sdsims = TRUE)
# Should result in adjusted alpha 0.03336 (TIE 0.5000, TIE for nominal alpha 0.07237).
#
# TRT|RTR, heteroscedasticity, sample size 48 (unbalanced), subject data simulations.

scABEL.ad(CV = c(0.25, 0.3), design = "2x2x3", n = c(23, 25), sdsims = TRUE)
# Should result in adjusted alpha 0.02465 (TIE 0.5000, TIE for nominal alpha 0.09050).
#
# TRTR|RTRT, CV 0.35, sample size 33 (unbalanced).

scABEL.ad(CV = 0.35, design = "2x2x4", n = c(16, 17))
# Should result in adjusted alpha 0.03632 (TIE 0.5000, TIE for nominal alpha 0.06544).
</code></pre>


</div>